BrightHeart’s AI for Prenatal Heart Defect Detection Receives FDA Clearance

Written By Amanda French

BrightHeart, a Paris-based AI company focused on obstetrics and pediatric cardiology, has demonstrated breakthrough results in improving detection of congenital heart defects (CHDs) during prenatal ultrasounds. The company also recently received FDA clearance for its innovative AI technology.

Amanda French
Previous

AI assistance improves CHD detection on prenatal ultrasound
Next

BrightHeart Unveils Breakthrough AI Results at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, Revolutionizing Prenatal Care